reported Monday.” data-reactid=”19″>The National Institutes Of Health is set to investigate a Gilead Sciences, Inc (NASDAQ: GILD) compound, similar to remdesivir, which could be effective against COVID-19, Stat reported Monday.
@NIHDirector @ncats_nih_gov @SteveFDA @GileadSciences
So grateful that NIH/NCATS evaluted the case for #GS441524 as a treatment for #COVID19 and have committed to invest the resources needed to support bringing this potentially game changing drug to clinical trials. pic.twitter.com/Gs2d0ncV9d
— Muller Lab (@Muller_Lab) August 23, 2020
Two researchers at the University of Texas MD Anderson Cancer Center have reportedly been arguing that the drugmaker should test the compound for effectiveness against COVID-19.
The researchers argued that GS-441524 is easier to synthesize compared to remdesivir and thus it should be easier to create higher oral doses.
Gilead claimed earlier that remdesivir is more effective in test tubes and animal models compared with its other compound in stopping viral replication, and is more active in lab tests against many types of coronaviruses including SARS-COV-2, Stat reported.
This month, the California-based drugmaker sought full approval from the Food and Drug Administration for remdesivir, which is approved for emergency use in COVID-19 patients.
View Article Origin Here